All results

5 results for randomized multicenter double blind placebo controlled parallel group phase 3 study

• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

  This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…

  Ages

  18 Years - N/A

  Sexes

  All

• Edgewise-210

  The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…

  Ages

  4 Years - 9 Years

  Sexes

  Male

• IMPALA-2

  160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…

  Ages

  18 Years - N/A

  Sexes

  All

• BLOCK-SAH

  BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of…

  Ages

  18 Years - 85 Years

  Sexes

  All

• GCAptAIN

  This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…

  Ages

  50 Years - N/A

  Sexes

  All